Drug Trial Radar · NCT04530110
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
499
Actual
Start
Sep 16, 2020
Primary completion
Aug 15, 2025
Study completion Dec 22, 2025
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
- Sponsor type
- Industry
- First posted
- Aug 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed to fremanezumab. The total duration of the study is planned to be up to 84 months.
Conditions
- Migraine
Interventions
FremanezumabDrug
Participants weighing ≥ threshold will receive Dose A subcutaneously monthly. Participants weighing \< threshold will receive Dose B subcutaneously monthly. Subcutaneously monthly, confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Day 1 up to Day 393
- Number of Participants With Potentially Clinically Significant Abnormal Laboratory (Serum Chemistry, Hematology, Coagulation, and Urinalysis) ResultsTime frame: Day 1 up to Day 253
- Number of Participants With Shift From Baseline to Last Assessment in Electrocardiogram (ECG) Findings (Assessed by Investigator)Time frame: Baseline to last assessment (up to Day 253)
- Number of Participants With Shift From Baseline to Last Assessment in ECG Findings (Assessed by Cardiologist)Time frame: Baseline to last assessment (up to Day 253)
- Number of Participants With Potentially Clinically Significant Vital Sign AbnormalitiesTime frame: Day 1 up to Day 253
- Number of Participants With Shift From Baseline to Last Assessment in Physical Examination FindingsTime frame: Baseline to last assessment (up to Day 393)
- Number of Participants With Suicidal Ideation or Behavior, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Day 1 up to Day 393
Locations
70 sites in 9 countries. Site status is shown where the registry gives one.
Teva Investigational Site 14319
Aurora, Colorado
Teva Investigational Site 14368
Colorado Springs, Colorado
Teva Investigational Site 14244
Jacksonville, Florida
Teva Investigational Site 14325
Miami, Florida
Teva Investigational Site 14250
West Palm Beach, Florida
Teva Investigational Site 14255
West Palm Beach, Florida
Teva Investigational Site 14243
Atlanta, Georgia
Teva Investigational Site 14258
Savannah, Georgia
Teva Investigational Site 14263
Hoffman Estates, Illinois
Teva Investigational Site 14245
Wichita, Kansas
Teva Investigational Site 14327
Louisville, Kentucky
Teva Investigational Site 14360
Covington, Louisiana
Teva Investigational Site 14365
Baltimore, Maryland
Teva Investigational Site 14246
Waltham, Massachusetts
Teva Investigational Site 14251
Ann Arbor, Michigan
Teva Investigational Site 14270
Minneapolis, Minnesota
Teva Investigational Site 14376
Ridgeland, Mississippi
Teva Investigational Site 14256
Bridgeton, Missouri
Teva Investigational Site 14371
New Brunswick, New Jersey
Teva Investigational Site 14276
Amherst, New York
Teva Investigational Site 14377
Durham, North Carolina
Teva Investigational Site 14248
Raleigh, North Carolina
Teva Investigational Site 14264
Cincinnati, Ohio
Teva Investigational Site 14257
Oklahoma City, Oklahoma
Teva Investigational Site 14363
Tulsa, Oklahoma
Teva Investigational Site 14364
Philadelphia, Pennsylvania
Teva Investigational Site 14374
Bristol, Tennessee
Teva Investigational Site 14252
Austin, Texas
Teva Investigational Site 14273
Austin, Texas
Teva Investigational Site 14367
Dallas, Texas
Teva Investigational Site 14375
Salt Lake City, Utah
Teva Investigational Site 14323
Norfolk, Virginia
Teva Investigational Site 11182
Ottawa, Ontario, Canada
Teva Investigational Site 11179
Ottawa, Ontario, Canada
Teva Investigational Site 11181
Montreal, Quebec, Canada
Teva Investigational Site 40053
Helsinki, Finland
Teva Investigational Site 40049
Kuopio, Finland
Teva Investigational Site 40054
Oulu, Finland
Teva Investigational Site 40052
Tampere, Finland
Teva Investigational Site 32728
Bad Homburg, Germany
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.